Search News
| 106.33 Delayed Data As of Sep 21 |  +0.26 / +0.25%Today’s Change | 73.69 Today|||52-Week Range 107.84 | +25.89% Year-to-Date |
| Market Rallies Despite Trade Worries: 5 Blue-Chip Picks Sep 21 / Zacks.com - Paid Partner Content | Does Ajovy's Approval Make Teva a Pain-Free Stock to Buy? Sep 18 / MotleyFool.com - Paid Partner Content |
| Eli Lilly Prices Animal Health Unit IPO at $24 Per Share Sep 20 / Zacks.com - Paid Partner Content | Is Galapagos NV a Buy Now? Sep 18 / MotleyFool.com - Paid Partner Content |
| J&J Files NDA for Erdafitinib in Urothelial Cancer Indication Sep 19 / Zacks.com - Paid Partner Content | Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV Sep 17 / Zacks.com - Paid Partner Content |
| Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff Sep 19 / Zacks.com - Paid Partner Content | Teva's (TEVA) Migraine Drug Ajovy Receives FDA Approval Sep 17 / Zacks.com - Paid Partner Content |
| Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern Sep 18 / Zacks.com - Paid Partner Content | Allergan Frown Lines Study Passes Test on Higher Botox Dose Sep 17 / Zacks.com - Paid Partner Content |
| Previous close | 106.07 |
| Today’s open | 106.23 |
| Day’s range | 105.35 - 106.87 |
| Volume | 5,333,680 |
| Average volume (3 months) | 3,589,063 |
| Market cap | $114.2B |
| Earnings growth (last year) | -107.36% |
| Earnings growth (this year) | +27.84% |
| Earnings growth (next 5 years) | +14.10% |
| Revenue growth (last year) | +7.77% |
| P/E ratio | NM |
| Price/Sales | 3.88 |
| Price/Book | 10.09 |
| Today’s change | Today’s % change | |
|---|---|---|
| SNYSanofi | -0.60 | -1.36% |
| ABTAbbott Laboratories | +0.26 | +0.38% |
| BMYBristol-Myers Squibb | +0.50 | +0.81% |
| GSKGlaxoSmithKline | +0.43 | +1.08% |
| Next reporting date | October 23, 2018 |
| EPS forecast (this quarter) | $1.35 |
| Annual revenue (last year) | $22.9B |
| Annual profit (last year) | -$204.1M |
| Net profit margin | -0.89% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chairman, President & Chief Executive Officer David A. Ricks |
Senior VP-Biotechnology & Autoimmunity Research Thomas F. Bumol |
Corporate headquarters Indianapolis, Indiana |
